JP2020530299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530299A5 JP2020530299A5 JP2020507586A JP2020507586A JP2020530299A5 JP 2020530299 A5 JP2020530299 A5 JP 2020530299A5 JP 2020507586 A JP2020507586 A JP 2020507586A JP 2020507586 A JP2020507586 A JP 2020507586A JP 2020530299 A5 JP2020530299 A5 JP 2020530299A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- appendix
- cell
- binding
- binding substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023103640A JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542920P | 2017-08-09 | 2017-08-09 | |
| US62/542,920 | 2017-08-09 | ||
| PCT/US2018/045741 WO2019032661A1 (en) | 2017-08-09 | 2018-08-08 | CD8 LIAISON AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103640A Division JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530299A JP2020530299A (ja) | 2020-10-22 |
| JP2020530299A5 true JP2020530299A5 (enExample) | 2021-09-16 |
| JP7347899B2 JP7347899B2 (ja) | 2023-09-20 |
Family
ID=65272669
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507586A Active JP7347899B2 (ja) | 2017-08-09 | 2018-08-08 | Ｃｄ８結合物質 |
| JP2023103640A Pending JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A Pending JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103640A Pending JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A Pending JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566072B2 (enExample) |
| EP (1) | EP3665201A4 (enExample) |
| JP (3) | JP7347899B2 (enExample) |
| CN (1) | CN111511763B (enExample) |
| CA (1) | CA3069930A1 (enExample) |
| WO (1) | WO2019032661A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6815196B2 (ja) | 2013-03-13 | 2021-01-20 | イマジナブ、 インコーポレイテッド | Ｃｄ８に対する抗原結合性構築物 |
| KR20250008141A (ko) | 2015-08-07 | 2025-01-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
| US11753463B2 (en) * | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| WO2019032661A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| EP3976650A1 (en) | 2019-05-28 | 2022-04-06 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
| CA3142738A1 (en) * | 2019-06-05 | 2020-12-10 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| PE20221449A1 (es) * | 2019-09-04 | 2022-09-21 | Genentech Inc | Agentes de union a cd8 y usos de los mismos |
| AU2020361683A1 (en) * | 2019-10-11 | 2022-05-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US20230293652A1 (en) * | 2020-07-07 | 2023-09-21 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| CN113956357B (zh) * | 2020-07-21 | 2024-02-20 | 苏州智核生物医药科技有限公司 | Cd8结合多肽及其用途 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
| CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| GB2638094B (en) | 2021-05-19 | 2026-03-04 | Asher Biotherapeutics Inc | IL-21 Polypeptides And Targeted Constructs |
| CN114230665B (zh) * | 2021-06-23 | 2024-03-22 | 苏州智核生物医药科技有限公司 | CD8α结合多肽及其用途 |
| WO2023076876A1 (en) * | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| CA3241112A1 (en) * | 2021-12-29 | 2023-07-06 | Arash Hatefi | Single-domain high affinity antibodies and methods of use thereof |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4655323A1 (en) * | 2023-01-27 | 2025-12-03 | Vrije Universiteit Brussel | Cd8b-binding polypeptides |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3115318B2 (ja) | 1989-08-22 | 2000-12-04 | イミュネックス・コーポレーション | Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| EP1161522B1 (en) | 1999-03-12 | 2006-07-26 | Ortho-McNeil Pharmaceutical, Inc. | Method of isolating cd8+ cells, and related hybridoma cells, antibodies and polypeptides |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| WO2007110231A2 (en) | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| EP2173377B1 (en) | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| PE20120630A1 (es) | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| EP4450523A3 (en) * | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| CA2866126A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| WO2014028560A2 (en) * | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US10101324B2 (en) * | 2012-12-03 | 2018-10-16 | The Regents Of The University Of California | Non-competitive immunoassays to detect small molecules using nanopeptamers |
| PL2953973T3 (pl) * | 2013-02-05 | 2020-01-31 | Vib Vzw | Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania |
| JP6815196B2 (ja) * | 2013-03-13 | 2021-01-20 | イマジナブ、 インコーポレイテッド | Ｃｄ８に対する抗原結合性構築物 |
| MX375441B (es) | 2013-07-18 | 2025-03-06 | Vib Vzw | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. |
| US9732135B2 (en) | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
| AU2014291961B2 (en) | 2013-07-19 | 2018-09-27 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted modified TNF family members |
| CA2919725C (en) | 2013-08-08 | 2023-04-18 | Cytune Pharma | An il-15 and il-15r.aplha. sushi domain based modulokines |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2017077382A1 (en) * | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| JP7204643B2 (ja) * | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019032661A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
-
2018
- 2018-08-08 WO PCT/US2018/045741 patent/WO2019032661A1/en not_active Ceased
- 2018-08-08 JP JP2020507586A patent/JP7347899B2/ja active Active
- 2018-08-08 EP EP18844218.0A patent/EP3665201A4/en active Pending
- 2018-08-08 CA CA3069930A patent/CA3069930A1/en active Pending
- 2018-08-08 US US16/634,325 patent/US11566072B2/en active Active
- 2018-08-08 CN CN201880065719.XA patent/CN111511763B/zh active Active
-
2022
- 2022-12-01 US US18/060,694 patent/US12448447B2/en active Active
-
2023
- 2023-06-23 JP JP2023103640A patent/JP2023112153A/ja active Pending
-
2025
- 2025-05-01 JP JP2025076447A patent/JP2025109736A/ja active Pending
- 2025-09-24 US US19/338,176 patent/US20260125473A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| JP2020506727A5 (enExample) | ||
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| JP2020530298A5 (enExample) | ||
| JP7656401B2 (ja) | バイシストロン性キメラ抗原受容体及びそれらの使用 | |
| US10738116B2 (en) | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors | |
| US10562952B2 (en) | Anti-CD276 chimeric antigen receptors | |
| JP2020505955A5 (enExample) | ||
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| JP2019534246A5 (enExample) | ||
| JP2024500847A5 (enExample) | ||
| JP2023546725A5 (enExample) | ||
| JP2024037918A (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| JP2016537966A (ja) | 分子 | |
| CN113862292A (zh) | 嵌合抗原受体、组合物以及方法 | |
| US10752667B2 (en) | EPHA3 and multi-valent targeting of tumors | |
| US20160333422A1 (en) | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors | |
| CN114364801A (zh) | 用于用抗bcma免疫治疗来治疗癌症的组合物和方法 | |
| JP2022512541A5 (enExample) | ||
| Siegemund et al. | IgG-single-chain TRAIL fusion proteins for tumour therapy | |
| CA3232668A1 (en) | Switch receptors using il-9 signaling domains | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2022516964A5 (enExample) | ||
| TWI868739B (zh) | 靶向kras g12v突變多肽的t細胞受體及其用途 | |
| WO2020176897A1 (en) | Chimeric antigen receptors and uses thereof |